Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry Picks Holes In UK Plans For Post-Brexit Drug Regulation

Executive Summary

Plans for a post-Brexit standalone regulatory system have drawn a mixed response from UK pharmaceutical industry bodies, which are worried about aspects of proposals on future drug approval routes, orphan and pediatric drug incentive schemes, and the “grandfathering” of existing EU marketing authorizations. They are also calling for financial compensation should the UK not be part of Europe's the new drug verification system.

You may also be interested in...



UK Govt Has ‘Made A Hash’ Of Managing Brexit For Life Sciences Sector

A recent debate in the House of Lords saw some fiery words exchanged over the government’s plans for the life science sector in the event of a no-deal Brexit, with accusations that they would produce a “clunky” regulatory system and put industry’s future “at grave risk.”

New UK Drug Assessment Routes Among Latest Measures For No-Deal Brexit

The UK MHRA has updated its guidance on how it plans to regulate medicines and healthcare products if the UK leaves the EU without a deal. Among many other things, it includes the promise of free scientific advice for SMEs and details on how marketing applications for centrally authorized products will be converted into UK ones in the event of a hard Brexit. 

UK Agency Boss Hudson Leaves Brexit Challenge To Successor

A new leader is needed for MHRA as UK agency CEO Ian Hudson announces he'll leave next September. Someone else will have to reshape and guide the agency after Brexit.

Related Content

Topics

UsernamePublicRestriction

Register

PS051363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel